Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Since when do you give "severance pay" to someone who resigned??? Feel free to look up the definition of "severance pay" and you'll find this: an amount paid to an employee upon dismissal or discharge from employment. Of course you give severance pay to someone who have been terminated (i.e. fired). THAT is what severance pay is!
You don't continue to pay someone for nine months after they resign. He was obviously fired, and you don't fire someone when they're doing a good job. They were nice enough to give him severance pay even though he didn't produce anything and consistently missed his deadlines.
What did he produce while he was there?? Anything??
And what proof do you have of this? Please feel free to share.
Clearly, with Rosenbomb being an attorney, I would think he could easily approach Mahboob and dig up some dirt, not that he probably hasn't already tried and failed. Perhaps that is what you meant when you said he's "silent" and won't give Rosenbomb what he wants.
Not true. I know someone who got fired for gross incompetence. He didn't produce anything for eight months.
Sure. They all got fired for being talented and ethical folks. lol
I can't. They've all been fired for incompetence.
I would suggest you start with the first PR. You'll quickly see there is NOWHERE that it says they are preventing shareholders from voting. It's real simple - if you own shares, you can vote. And the number of shares you have will equal the number of votes you have.
Yes, please contact SA because I'd like to see where they are trying to keep shareholders from voting. Perhaps you're getting confused with "who" they will be voting for.
I'm not aware of anyone who's trying to keep shareholders from voting.
That's an easy one. 13D gang! Why would anyone think otherwise given they've created a very toxic environment with their hostile takeover attempt (that won't succeed).
Please feel free to share the "little info" released by CYDY's CFO. I'm anxious to see the part that would support the claim that it will make the RTF letter a "scathing embarrassment".
I agree. The 13D gang can't be trusted!!! Where's the plan??? Where's the beef???
Oh, that's right...we'll see it in late Oct. It'll be sssoooooo good!
All Trick and NO treat!!!
Yes, but it IS a Plan!
So while everyone is whining about not seeing the RTF letter (nor should they given it's a confidential communication between the FDA and CYDY), you're now saying it includes the following without having seen it? What else does the RTF letter contain that you haven't seen?
"Maybe"?? Like "maybe" the 13D gang has a plan.
Well stated.
If you don't know what's in it, then how do you know it will show that he's incompetent??
What is in the RTF that will officially show his incompetence?
Please, please, please feel free to share just one tidbit of the 13D plan. I'm waiting with baited breath...
Is this the same miracle drug that you described as a saline placebo? The same "Miracle Drug" that was described as "the fairy tale that Leronlimab's performance is just statistical noise" a couple of days after you requested it from Kelly?
Well that is a "miracle" given that CYDY announced last week that they are no longer able to provide LL under Right to Try because they needed to reserve Leronlimab for the Brazil trials.
CYDY's execution of their business plan is shared with us daily. Take this morning's PR for example, about their progress in treating mTNBC - great news, isn't it?
Now, for the 13D business plan. It's been 3 months - where is it? Where's the beef??? (insert crickets chirping). Oh, yeah, it's such a good plan that they can't share it with us until we get close to the end of Oct. It's sssoooooo good that they're keeping it under wraps. Now THAT's a business plan!!! Can't wait to vote for them so I can find out what else is in their business plan that is in addition to merging INcellDX with CytoDyn and then selling off Leronlimab to the highest bidder. Can't wait for that one!
Thanks for presenting the facts. They're a rare commodity these days when it comes to the real history behind Leronlimab. Such an incredible drug, and such a shame that so many people are trying to keep those who need it from getting it.
The fact the 13D gang is soliciting proxy votes in August when the Record Date of share ownership isn't until Sept 1 is nothing less than laughable.
It appears the 13D gang aren't taking this morning's great mTNBC news very well. It's just another triumphant step for Nader and the CYDY management team which means the 13D gang will now have to work much harder trying to convince everyone they can do better.
Which market are you referring to? The one that's up over 6%? I think we all need to be a little patient and not assume everyone has seen this morning's PR.
More importantly - don't forget this headline:
CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival
Here you go in case you missed it:
CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival
VANCOUVER, Washington, Aug. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today an update to previously reported preliminary results from its Phase 1b/2 trials and compassionate use with leronlimab to treat a total of 30 metastatic triple-negative breast cancer (mTNBC) patients.
Decrease in Circulating Tumor Cells (CTC) as reported using the LifeTracDx™ test developed by Creatv MicroTech, Inc., after induction with leronlimab was associated with a 400%-660% increase in mPFS (modified Progression Free Survival)/12-month PFS (Progression Free Survival) and a 570%-980% increase in mOS (modified Overall Survival) /12-month OS (Overall Survival). Decreases in CTC after leronlimab induction were seen in 73% of the 30 patients in the study. LifeTracDx™ appears to aid as a parallel diagnostic tool in identifying patients that respond to leronlimab.
Data from these 30 patients are aligned with the premise that a majority of mTNBC patients respond to leronlimab if CTC reduction is observed following one leronlimab dose.
Scott Kelly, M.D., CytoDyn’s Chief Medical Officer and Chairman of the Board, commented, “We are delighted with the results of both mPFS and mOS when compared to the Standard of Care treatment for mTNBC across Emergency Use, Compassionate Use, mTNBC, and our Basket Trial. We anticipate the demand for new therapeutic options with limited toxicity and enhanced convenience for the patient to grow exponentially over the next decade. We believe this is further evidence that leronlimab has a promising role in the future of oncology to help alleviate the burden of cancer on patients and their loved ones. We are exploring opportunities to enhance our oncology platform through pharmacological partnerships, academic partnerships, and research on combining synergistic benefits of leronlimab in the tumor microenvironment.”
Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, added, “This report of results for 30 patients suggests that, with one blood test, we may be able to predict which mTNBC patients will respond well to leronlimab, which is a truly remarkable finding. These exploratory findings will now enable us to proceed for further regulatory review. With today’s report, we are delighted that we are presented with the possibility of achieving first approval with HIV, COVID-19 or possibly now cancer. We are grateful for the multiple opportunities we have had to create and explore as possible uses for this wonderful drug, leronlimab. The testimonies of physicians and patients about the use of leronlimab in cancer, COVID-19, and HIV has been nothing short of a dream come true for me.”
https://www.cytodyn.com/investors/news-events/press-releases/detail/551/cytodyns-final-mtnbc-report-indicates-as-much-as-980
The stock chart proves your comments about this morning's PR that Leronlimab extended the life of mTNBC patients by 980% didn't really happen??? LOL
Yes, I let people know that what I'm saying is my opinion unless, of course, I provide a link to the facts. The easiest way to determine when someone claims to have the "facts" about CytoDyn is when they can't provide a link that supports their "opinions". This is why I'm still waiting for the "proof".
CytoDyn Urges Shareholders to Ignore Proxy Cards from Rosenbaum/Patterson Group
Shareholders Using the Group’s Proxy Card Risk Not Having Their Votes Counted at Annual Meeting
Federal Court Grants CytoDyn’s Motion for Expedited Discovery from the Rosenbaum/Patterson Group
Shareholders Do Not Need to Take Any Action at this Time
VANCOUVER, Wash.--(BUSINESS WIRE)-- The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today issued the following statement to shareholders:
“Shareholders may have received proxies from the activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group” or the “Group”) seeking your votes to take over a majority of the CytoDyn Board. We urge you to ignore these proxy cards. You will be receiving proxy materials from us in due course and you do not need to take any action at this time.
Troublingly, the Rosenbaum/Patterson Group has failed to disclose, in clear and prominent language, in its proxy materials, that shareholders using the Group’s proxy card risk being disenfranchised and not having their votes counted at all.
As we have publicly stated before, CytoDyn informed the Group on July 30, 2021 that its notice of the nomination of five director candidates for the 2021 Annual Meeting was invalid because it failed to comply with the Company’s by-laws. Therefore, the Group’s director nominations will be disregarded, and no proxies or votes in favor of its nominees will be recognized or tabulated at the 2021 Annual Meeting.
Moreover, please do not be misled by the Group’s claim that “the SEC cleared [the Group] to file [its] definitive Proxy Statement.”1 According to the SEC’s proxy rules, the fact that a proxy statement has been filed with or examined by the SEC staff shall not be deemed a finding by the SEC that such proxy statement is accurate or complete or not false or misleading, or that the SEC has passed upon the merits of or approved any statement contained therein.2
The accuracy of the Group’s proxy statement is at issue in the pending litigation brought by CytoDyn in the U.S. District Court for the District of Delaware.3 The Rosenbaum/Patterson Group previously contended that they had supplemented their proxy statement and that no discovery should proceed because the lawsuit was moot. In a recent development in this case, however, yesterday the federal Court granted the Company’s Motion for Expedited Discovery and Expedited Proceedings, noting “the need for urgent action to avoid potential irreparable harm”. A copy of the Court’s order has been filed with the SEC on a Current Report on Form 8-K.
To reiterate, we urge shareholders to ignore the emails and mailings of the Rosenbaum/Patterson Group. Shareholders do not need to take any action at this time, and will be receiving our proxy materials in the coming weeks. To the extent shareholders have voted on the Group’s proxy card, they can vote on the Company’s proxy card once it becomes available to revoke their vote on the Group’s card. Only the latest-dated proxy card counts.
We will continue to update you on these matters as events warrant. Rest assured that we are focused on acting in the best interests of all shareholders as we work to secure approval for leronlimab and bring its lifesaving potential to market.”
https://www.cytodyn.com/newsroom/press-releases/detail/552/cytodyn-urges-shareholders-to-ignore-proxy-cards-from
Click on your link and it says "Page not Found". LOL
Must be the browser again... LOL
What I asked for is "proof" - not opinion.
Please feel free to provide ANYTHING that shows proof that it didn't extend life by 980%.
The issue isn't with the translation. The issue is how a picture of it was photoshopped to support the false narrative that it was NOT approved for treating moderately ill patients.
CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival
VANCOUVER, Washington, Aug. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today an update to previously reported preliminary results from its Phase 1b/2 trials and compassionate use with leronlimab to treat a total of 30 metastatic triple-negative breast cancer (mTNBC) patients.
Decrease in Circulating Tumor Cells (CTC) as reported using the LifeTracDx™ test developed by Creatv MicroTech, Inc., after induction with leronlimab was associated with a 400%-660% increase in mPFS (modified Progression Free Survival)/12-month PFS (Progression Free Survival) and a 570%-980% increase in mOS (modified Overall Survival) /12-month OS (Overall Survival). Decreases in CTC after leronlimab induction were seen in 73% of the 30 patients in the study. LifeTracDx™ appears to aid as a parallel diagnostic tool in identifying patients that respond to leronlimab.
Data from these 30 patients are aligned with the premise that a majority of mTNBC patients respond to leronlimab if CTC reduction is observed following one leronlimab dose.
Scott Kelly, M.D., CytoDyn’s Chief Medical Officer and Chairman of the Board, commented, “We are delighted with the results of both mPFS and mOS when compared to the Standard of Care treatment for mTNBC across Emergency Use, Compassionate Use, mTNBC, and our Basket Trial. We anticipate the demand for new therapeutic options with limited toxicity and enhanced convenience for the patient to grow exponentially over the next decade. We believe this is further evidence that leronlimab has a promising role in the future of oncology to help alleviate the burden of cancer on patients and their loved ones. We are exploring opportunities to enhance our oncology platform through pharmacological partnerships, academic partnerships, and research on combining synergistic benefits of leronlimab in the tumor microenvironment.”
Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, added, “This report of results for 30 patients suggests that, with one blood test, we may be able to predict which mTNBC patients will respond well to leronlimab, which is a truly remarkable finding. These exploratory findings will now enable us to proceed for further regulatory review. With today’s report, we are delighted that we are presented with the possibility of achieving first approval with HIV, COVID-19 or possibly now cancer. We are grateful for the multiple opportunities we have had to create and explore as possible uses for this wonderful drug, leronlimab. The testimonies of physicians and patients about the use of leronlimab in cancer, COVID-19, and HIV has been nothing short of a dream come true for me.”
https://www.cytodyn.com/investors/news-events/press-releases/detail/551/cytodyns-final-mtnbc-report-indicates-as-much-as-980
Everyone has seen the photoshopped pictures, many of them including myself have taken snapshots and forwarded them to CYDY legal and the SEC. It's called "market manipulation" and is highly illegal.
Good luck!
Yes, the translation of his new link doesn't match the photo in his previous post. Anyone can see this.
And if you look at the photo, you can see where "in" was photoshopped and replaced with "and not". Very sloppy job.